Department of Nephrology, Fujita Health University Hospital, 1-98 Dengakugakubo Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
Clin Exp Nephrol. 2013 Apr;17(2):218-24. doi: 10.1007/s10157-012-0679-2. Epub 2012 Aug 29.
To clarify the therapeutic impact of tonsillectomy and combined therapies of tonsillectomy plus steroid on the long-term prognosis of immunoglobulin A nephropathy (IgAN).
A retrospective study was conducted on 208 patients with IgAN between 1986 and 2009. According to the strategies for treatments, patients were divided into four groups: tonsillectomy and steroid pulse (TSP, n = 47), tonsillectomy and oral steroid (TOS, n = 33), tonsillectomy alone (T, n = 56), and N group (no particular therapy, n = 72). Multivariate analysis based on the Cox's regression model was used to assess the relative risk of reaching the outcome of doubling creatinine based on the influence of baseline prognostic factors.
The mean observation periods were 53.8 months in the TSP group, 122.0 months in the TOS group, 102.9 months in the T group, and 84.6 months in the N group. During an observation period, serum creatinine levels doubled as follows: one in the TSP group (2.1 %), two in the TOS group (6.1 %), five in the T group (8.9 %), histological severity, and 22 in the N group (30.6 %). The Cox's regression proportional hazard model showed that gender, age, histological activity, dialysis induction risk and therapy were associated with doubling creatinine levels. Hazard ratios (95 % CI) and (P value) in T, TOS, and TSP groups versus N were 0.314 (0.11-0.93, P = 0.037), 0.213 (0.04-1.10, P = 0.065), and 0.032 (0.00-0.28, P = 0.002), respectively.
A combination therapy of tonsillectomy and steroid pulse had the most significant therapeutic impact compared to other therapies.
为阐明扁桃体切除术和扁桃体切除术联合类固醇治疗对 IgA 肾病(IgAN)长期预后的治疗影响。
对 1986 年至 2009 年间 208 例 IgAN 患者进行回顾性研究。根据治疗策略,患者分为四组:扁桃体切除术和类固醇脉冲(TSP,n=47)、扁桃体切除术和口服类固醇(TOS,n=33)、单纯扁桃体切除术(T,n=56)和 N 组(无特殊治疗,n=72)。基于 Cox 回归模型的多变量分析用于评估基于基线预后因素的影响,达到肌酐加倍结局的相对风险。
TSP 组平均观察期为 53.8 个月,TOS 组为 122.0 个月,T 组为 102.9 个月,N 组为 84.6 个月。在观察期内,血清肌酐水平加倍情况如下:TSP 组 1 例(2.1%)、TOS 组 2 例(6.1%)、T 组 5 例(8.9%)、组织学严重程度和 N 组 22 例(30.6%)。Cox 回归比例风险模型显示,性别、年龄、组织学活动、透析诱导风险和治疗与肌酐加倍水平相关。T、TOS 和 TSP 组与 N 组相比,危险比(95%CI)和(P 值)分别为 0.314(0.11-0.93,P=0.037)、0.213(0.04-1.10,P=0.065)和 0.032(0.00-0.28,P=0.002)。
与其他治疗方法相比,扁桃体切除术联合类固醇脉冲治疗具有最显著的治疗效果。